Medincell SA (MEDCL PA) stock market data APIs
€26.1124
0.89(3.4%)
as of May 7, 2026
Try our APIs with
free plan!
Medincell SA Financial Data Overview
Price chart is built with
Anychart
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation in total knee arthroplasty surgery. In addition, its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. It has strategic collaborations with AbbVie to develop, manufacture, and commercialize six long-acting injectable therapeutic products; and IM4TB to develop a long-acting injectable version of Macozinone for the treatment of tuberculosis. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.
Prev. Close
26.1124
Open
26.9979
High
27.1499
Low
25.9162
52 wk Range
14.5-39.68
Market Cap
946 M
Shares Outstanding
35 907 K
Revenue
32 439 K
EPS
0
Beta
1
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Medincell SA (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Medincell SA data using free add-ons & libraries
Get Medincell SA Fundamental Data
Medincell SA Fundamental data includes:
- Net Revenue: 32 439 K
- EBITDA: -9 569 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-25
- EPS/Forecast: -0.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Medincell SA News
New
Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year
MONTPELLIER, France, April 29, 2026--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY U.S. net sales...
Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Olanzapine long-acting injectable suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1 If approved, TEV-'749 could help address a s...
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Teva Pharmaceutical Industries Ltd Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1 If ...
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)
OLANZAPINE LAI: EU Submission Expected in Q2 2026 MONTPELLIER, France, January 28, 2026--(BUSINESS WIRE)--Regulatory News: Medincell’s (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the...
Get Medincell SA fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
